ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical
stage specialty biopharmaceutical company developing first-in-class
drugs for treatment of inflammatory and renal diseases, announces
publication of an article in the peer-reviewed journal, Aging,
demonstrating that inflammasome NLRP3 activation is associated with
an age-related decline in kidney health, which is compounded in the
presence of kidney disease resulting in worsening outcomes.
In the paper titled, “Inhibiting NLRP3 signaling in aging
podocytes improves their life-and health-span,” the authors
conducted studies in various mouse models, human kidney tissues,
and human kidney organoids. Data demonstrate a critical role for
NLRP3 inflammasomes in age-related kidney deterioration, which is
exacerbated in the presence of kidney disease. Following are key
findings reported in the paper:
- Glomerular NLRP3 levels in human
kidney tissue were associated with pathological changes in the
kidneys’ filtration system: higher levels of glomerular scarring
(glomerulosclerosis) and enlargement (hypertrophy), and reduced
podocyte density.
- Glomerular NLRP3 inflammasome levels
were higher in aged mice with experimental focal segmental
glomerulosclerosis (FSGS) compared to age-matched mice without
disease, indicating that FSGS injury augments the age-dependent
increase of NLRP3 signaling.
- NLRP3 inflammasome signaling and its
effects on podocytes may be a critical contributor to a lower
threshold for developing kidney disease in older people.
- Reduction in NLRP3 signaling, either
pharmacologically or by gene deletion, in human kidney organoids
and in middle-aged mice decreased age-associated podocyte
injury.
The authors stated, “By showing that in aged mice with
experimental FSGS, injury augments the age-dependent increase of
NLRP3 signaling, it makes this pathway an intriguing therapeutic
target for podocyte (kidney) diseases in the elderly.” To read the
article, Click Here.
“The research published in the Journal, Aging, demonstrates that
age-related NLRP3 inflammasome signaling in the kidneys’ filtration
system leads to scarring and podocyte loss, which are exacerbated
when superimposed by kidney disease, leading to poorer outcomes,”
commented Stephen C. Glover, ZyVersa’s Co-founder, Chairman, CEO
and President. “This research provides support for inflammasome
inhibition as a promising treatment option for kidney disease,
which is most common in the elderly. ZyVersa is developing
Inflammasome ASC inhibitor IC 100. Unlike NLRP3 inhibitors,
designed to inhibit formation of the NLRP3 inflammasome to block
initiation of the inflammatory cascade, IC 100 was designed to
inhibit formation of multiple types of inflammasomes, and to
uniquely inhibit their associated ASC specks to block perpetuation
of damaging inflammation.” To review a white paper summarizing the
mechanism of action and preclinical data for IC 100, Click
Here.
About Inflammasome ASC Inhibitor IC 100
IC 100 is a novel humanized IgG4 monoclonal antibody that
inhibits the inflammasome adaptor protein ASC. IC 100 was designed
to attenuate both initiation and perpetuation of the inflammatory
response. It does so by binding to a specific region of the ASC
component of multiple types of inflammasomes, including NLRP1,
NLRP2, NLRP3, NLRC4, AIM2, Pyrin. Intracellularly, IC 100 binds to
ASC monomers, inhibiting inflammasome formation, thereby blocking
activation of IL-1β early in the inflammatory cascade. IC 100 also
binds to ASC in ASC Specks, both intracellularly and
extracellularly, further blocking activation of IL-1β and the
perpetuation of the inflammatory response that is pathogenic in
inflammatory diseases. Because active cytokines amplify adaptive
immunity through various mechanisms, IC 100, by attenuating
cytokine activation, also attenuates the adaptive immune
response.
About ZyVersa Therapeutics, Inc.
ZyVersa (Nasdaq: ZVSA) is a clinical stage specialty
biopharmaceutical company leveraging advanced, proprietary
technologies to develop first-in-class drugs for patients with
renal and inflammatory diseases who have significant unmet medical
needs. The Company is currently advancing a therapeutic development
pipeline with multiple programs built around its two proprietary
technologies – Cholesterol Efflux Mediator™ VAR 200 for treatment
of kidney diseases, and Inflammasome ASC Inhibitor IC 100,
targeting damaging inflammation associated with numerous CNS and
other inflammatory diseases. For more information, please visit
www.zyversa.com.
Cautionary Statement Regarding Forward-Looking
Statements
Certain statements contained in this press release regarding
matters that are not historical facts, are forward-looking
statements within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended, and the Private Securities
Litigation Reform Act of 1995. These include statements regarding
management’s intentions, plans, beliefs, expectations, or forecasts
for the future, and, therefore, you are cautioned not to place
undue reliance on them. No forward-looking statement can be
guaranteed, and actual results may differ materially from those
projected. ZyVersa Therapeutics, Inc (“ZyVersa”) uses words such as
“anticipates,” “believes,” “plans,” “expects,” “projects,”
“future,” “intends,” “may,” “will,” “should,” “could,” “estimates,”
“predicts,” “potential,” “continue,” “guidance,” and similar
expressions to identify these forward-looking statements that are
intended to be covered by the safe-harbor provisions. Such
forward-looking statements are based on ZyVersa’s expectations and
involve risks and uncertainties; consequently, actual results may
differ materially from those expressed or implied in the statements
due to a number of factors, including ZyVersa’s plans to develop
and commercialize its product candidates, the timing of initiation
of ZyVersa’s planned preclinical and clinical trials; the timing of
the availability of data from ZyVersa’s preclinical and clinical
trials; the timing of any planned investigational new drug
application or new drug application; ZyVersa’s plans to research,
develop, and commercialize its current and future product
candidates; the clinical utility, potential benefits and market
acceptance of ZyVersa’s product candidates; ZyVersa’s
commercialization, marketing and manufacturing capabilities and
strategy; ZyVersa’s ability to protect its intellectual property
position; and ZyVersa’s estimates regarding future revenue,
expenses, capital requirements and need for additional
financing.
New factors emerge from time-to-time, and it is not possible for
ZyVersa to predict all such factors, nor can ZyVersa assess the
impact of each such factor on the business or the extent to which
any factor, or combination of factors, may cause actual results to
differ materially from those contained in any forward-looking
statements. Forward-looking statements included in this press
release are based on information available to ZyVersa as of the
date of this press release. ZyVersa disclaims any obligation to
update such forward-looking statements to reflect events or
circumstances after the date of this press release, except as
required by applicable law.
This press release does not constitute an offer to sell, or the
solicitation of an offer to buy, any securities.
Corporate and IR Contact:Karen CashmereChief
Commercial Officerkcashmere@zyversa.com786-251-9641
Media ContactsTiberend Strategic Advisors,
Inc.Casey McDonaldcmcdonald@tiberend.com646-577-8520
Dave Schemeliadschemelia@tiberend.com609-468-9325
ZyVersa Therapeutics (NASDAQ:ZVSA)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
ZyVersa Therapeutics (NASDAQ:ZVSA)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024